Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.

Journal of translational medicine - 24 Jul 2025

Yang Xuanhua, Feng Shiwei, Zhang Qi, Li Wenxin, Li Shujuan, Zhi Min, Lan Ping, Cheng Sijing

Abstract excerpt

BACKGROUND: Kirsten Rat Sarcoma (KRAS) copy number amplification has emerged as an oncogenic driver in colorectal cancer (CRC), in addition to KRAS mutation. However, its clinical significance remains poorly understood. Notably, CRC patients with wild-type KRAS but harboring KRAS amplification have shown resistance to anti-EGFR therapy, representing an unmet clinical need. METHODS: In this study, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Targeted Therapy

Share to Proto-Oncogene Proteins p21(ras)

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40708044
DOI: 10.1186/s12967-025-06864-x
PMCID: PMC12291525

Genes

KRAS
CDK4
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS amplification in colorectal cancer: correlations with clinicopathological features and prognosis in patients and prediction of response to targeted therapy.PMID 40708044Read ↗

Prevalence of KRAS amplification in patients with metastatic cancer: Real-world next-generation sequencing analysis.Semantic proximity Read ↗

Comprehensive genomic profiling reveals prognostic signatures and insights into the molecular landscape of colorectal cancerSemantic proximity Read ↗

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapySemantic proximity Read ↗

Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.Semantic proximity Read ↗

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancerSemantic proximity Read ↗

Targeting the KRAS Oncogene for Patients with Metastatic Colorectal CancerSemantic proximity Read ↗

Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.Semantic proximity Read ↗

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.Semantic proximity Read ↗

Molecular and functional profiling unravels targetable vulnerabilities in colorectal cancerSemantic proximity Read ↗

Identification of Druggable Cancer Driver Genes Amplified across TCGA DatasetsSemantic proximity Read ↗

Integrated analysis of gene expression and copy number identified potential cancer driver genes with amplification-dependent overexpression in 1,454 solid tumorsSemantic proximity Read ↗

The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.